We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Physiomics Plc | LSE:PYC | London | Ordinary Share | GB00BDR6W943 | ORD 0.4P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.70 | 923,769 | 08:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 0.65 | 0.75 | 0.70 | 0.70 | 0.70 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 597k | -477k | -0.0023 | -3.04 | 1.42M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 15:58:51 | O | 6,309 | 0.665 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 02/10/2024 | 07:00 | UK RNS | Physiomics PLC New Services Launch and Website Update |
| 27/9/2024 | 19:53 | ALNC |  EARNINGS: Mulberry profit slumps, announces GBP10 million fundraise |
| 27/9/2024 | 07:00 | UK RNS | Physiomics PLC Annual Financial Report |
| 19/9/2024 | 07:00 | UK RNS | Physiomics PLC Notice of Results and Investor Presentation |
| 17/9/2024 | 15:36 | ALNC | Physiomics celebrates contract with existing client worth GBP65,000 |
| 17/9/2024 | 07:00 | UK RNS | Physiomics PLC Contract Award |
| 05/7/2024 | 14:57 | ALNC | TRADING UPDATES: Time Out opens new Barcelona site; US Solar NAV down |
| 05/7/2024 | 07:00 | UK RNS | Physiomics PLC Result of WRAP Retail Offer |
| 03/7/2024 | 12:09 | ALNC | TRADING UPDATES: Topps Tiles sales dip; Physiomics completes placing |
| 03/7/2024 | 07:00 | UK RNS | Physiomics PLC WRAP Retail Offer for up to £25,000 |
Physiomics (PYC) Share Charts1 Year Physiomics Chart |
|
1 Month Physiomics Chart |
Intraday Physiomics Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 10/10/2024 | 17:45 | Physiomics - Cancer Treatment tech firm working with Merck + Oxford Uni | 11,589 |
| 17/6/2021 | 07:23 | PHYSIOMICS plc Virtual Tumor platform | 4,957 |
| 28/3/2021 | 22:05 | Physiomics PYC 2021 DISCUSSION (MODERATED) | 5 |
| 22/12/2020 | 11:36 | 3 Years ago today | 2 |
| 29/11/2020 | 14:53 | 3 Years ago today | - |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2024-10-14 14:58:52 | 0.67 | 6,309 | 41.95 | O |
| 2024-10-14 14:05:15 | 0.67 | 100,000 | 665.00 | O |
| 2024-10-14 13:52:03 | 0.70 | 20,000 | 140.30 | O |
| 2024-10-14 13:40:02 | 0.67 | 6,328 | 42.08 | O |
| 2024-10-14 11:01:12 | 0.70 | 70,707 | 496.01 | O |
| Top Posts |
|---|
Posted at 14/10/2024 09:20 by Physiomics Daily Update Physiomics Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker PYC. The last closing price for Physiomics was 0.70p.Physiomics currently has 203,210,000 shares in issue. The market capitalisation of Physiomics is £1,422,470. Physiomics has a price to earnings ratio (PE ratio) of -3.04. This morning PYC shares opened at 0.70p |
Posted at 03/10/2024 00:37 by davevt Raven, if you want to talk about other shares, go and do it on those boards. This is pyc discussion. |
Posted at 02/10/2024 07:37 by recordz 2 October 2024Physiomics plc ("Physiomics" or the "Company") New Services Launch and Website Update Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce the official launch of its Biostatistics offering and expansion of its Data Science and Bioinformatics services. Leveraging its existing expertise and capabilities across the core Modelling and Simulation service line, the Company is moving forward to expand its offering into the synergistic service areas of Biostatistics and Data Science; both of which play crucial roles in drug development. Biostatistics: Biostatistics is an essential component of clinical research. It plays a pivotal role in the setup, conduct and reporting of all trials, regardless of therapeutic area, ensuring studies are well designed, data is accurately collected and analysed, and the results are interpreted correctly. For example, during the design of interventional trials, biostatistics is used to calculate the optimum number of patients to be recruited and help define what data should be collected so that the effect of the therapy can be detected, balancing this against the size and cost of the trial. The strategic rationale for Physiomics to develop the new Biostatistics services is three-fold. Firstly, the application of Modelling & Simulation and Biostatistics in drug development overlaps, with often the output of the former being a key input to the latter, allowing for natural follow-on work to be offered to clients. Secondly, biostatistics is a necessary component to the setup, conduct and reporting of any interventional clinical trial, from Phase 1 through to Phase 4, regardless of the therapeutic area. This opens a significant market for the Company, giving greater opportunity to scale. Finally, with both service lines utilising the same business model and similar expertise across mathematics and data science, this allows the Company to operate flexible staffing across service lines to meet demand and maximise utilisation. Data Science and Bioinformatics: Data Science and Bioinformatics have also become critical capabilities across the drug development continuum. From discovery through into the clinic, the volume and complexity of data being generated is increasing significantly, driven in part by advancements in technologies and regulatory pressures. Being able to effectively make use of this often-disparate data and derive insights from it is often where the challenge lies for drug developers. Data science and Bioinformatics tools and methodologies allow for the effective selection, curation, analysis and visualisation of this data. The Company has already been leveraging Data Science and Bioinformatics tools and methodologies as part of its core Modelling and Simulation service line, selecting and curating data required to develop and calibrate its models. The opportunity to use these tools and models outside Modelling and Simulation has become more apparent, with the Company delivering on its first pure Data Science and Bioinformatics project earlier in the year. During this project, the Company supported the client capture and curated a wide range of publicly available data relating to novel oncology drug targets. The data was processed and then presented in a form that allowed the client to determine the optimum drug target across a variety of tissue types. Physiomics is keen to build upon this success and identify new opportunities in this space. Launch: As of 30 September 2024, Physiomics has officially launched its new Biostatistics offering, as well as its expanded offering in Data Science and Bioinformatics, allowing the Company to offer a more integrated offering to its clients. To coincide with this, the Company has completed an update of its website (www.physiomics.co.u Dr Peter Sargent, CEO, commented: "We are delighted to have launched the new Biostatistics service line, as well as expand our Data Science and Bioinformatics Services. Not only can we now provide our clients a great breadth of services to support their drug development efforts, but these new services are an important component of the Company's growth strategy." |
Posted at 01/10/2024 18:23 by davevt This share has consistently dropped from 10p down to what it is now, year after year with increased turnover...so turnover has nothing to do with share price. |
Posted at 01/10/2024 17:54 by ravenrussia Hi DaveI don't think anything is priced in at the moment when other share are valued at sometimes 10,20 or 30 times turnover Any shares you would suggest looking into please ? |
Posted at 01/10/2024 12:43 by davevt Raven, right, so it's currently priced into the current share price, as it's foreknowledge. |
Posted at 30/9/2024 17:19 by davevt Raven, so if we already know the expected turnover is going to be 1.7m, that's now priced into the share price, as it's public knowledge. |
Posted at 05/9/2024 18:16 by thiopia The New CEO has a background at Innovate UK which has funded a lot of PYC workPYC are working on interesting new A I. Precision Medicine/Dosing tech with other innovative Companies like DoseMeRX and Beyond Blood Diagnostics... a start up Company involved in this field would be worth 10s of millions given the capital and man hours invested to date and the quality of the partnerships etc Unfortunately a lot of the Market judge Physiomics on the history of its mainly being a consultancy rather than the exciting innovative growth concept story nested within it. Current Market Cap of £1.5m is ridiculous. |
Posted at 07/6/2024 17:07 by davevt 'The project is valued at £161,580 and is anticipated to be completed over the next five months. The project, and associated contract award, is one of the two referred to in the Company's trading update on 3 May 2024'So, already priced in to the share price. |
Posted at 27/9/2023 14:00 by davevt '. Make no mistake pyc jumped 100% on a 150k contract so imagine what it will do when a multi million contract lands.'Not strictly true...only a few weeks ago the price was mid 2 and we had a 1p placing...so all it did was bring the price back right to where it was. If you think contracts this company gets raises the share price, you're in for a rude awakening. And pyc can't, or ever have ' multi million contract'...pyc dictate the price, and they charge around 35k for a pre clinical model and around 120 for a clinical model...because it takes so much longer. So the only way you could have a 'million' contract, is if by sheer chance, a drug company has 30 new drugs, all at the same time, for pyc to dose predict....ignoring the fact pyc only can work on about 4 to 5 projects a year. |
Posted at 08/9/2023 10:26 by davevt 'You've got this back to front. If they're feeding in data from a clinical trial to see if their computer comes up with the same results then that is not computer modelling, that's simply data analysis. The new guidance from the FCA is that they want to see results from computer modelling before they approve clinical trials.' Totally correct. Pyc do not do what you think they do. Think about it. Say a company comes to pyc and says 'hi, we want you to dose predict our new drug'...how the hell can pyc do anything without having data about how the drug works in the first place... Pyc will build a model of their prediction, give it to the client, and the client will run it along side their manual trial, and what the end result was, and who got the best one. If pycs prediction was top, they may get repeat work, if pycs model wasn't as good as the manual trial, pyc will then take the data and results from the trial to improve their model. The computers aren't psychic dude. It can't just model predict out of thin air. Maybe you're not aware, but the drugs pyc work on have 'already' been created and are known to work. All pyc is doing is trying to work out an 'optimum' dose. the drug company already has data on general dosing that works, and will give that data to pyc. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
